Bull
$96.20
Scenario price
$84.070
-0.118 (-0.14%)At close
SS&C Technologies Holdings, Inc. is a provider of services and software for the financial services and healthcare industries. Its portfolio of products and software-enabled services allows our financial services clients to automate and integrate front-office functions such as trading and modeling, middle-office functions such as portfolio management and reporting, and back-office functions such as accounting, performance measurement, reconciliation, reporting, processing and clearing, and compliance and tax reporting. The Company provides its solutions within the institutional asset and wealth management, alternative investment management, brokerage, retirement, financial advisory and financial institutions vertical markets. It provides solutions to the healthcare industry, including pharmacy, healthcare administration and health outcomes optimization solutions. Its healthcare solutions include claims adjudication, benefit management, care management and business intelligence services.
SS&C Technologies is a good buy right now due to its strong fundamentals and positive market sentiment. The current price is $84.07, with a forward P/E ratio of 10.62, suggesting it is undervalued compared to its growth potential. Additionally, the RSI of 84.34 indicates strong momentum, although it is approaching overbought territory. The main risk is the recent YTD change of -1.96%, which reflects broader market pressures, but the company’s solid earnings growth and optimistic forecasts provide a strong counterbalance.
RBC Capital
$101
2026-08-31
RBC Capital
2026-08-31
Price Target
$101
RBC Capital
$92
2026-07-24
RBC Capital
2026-07-24
Price Target
$92
Jefferies
$83
2026-07-20
Jefferies
2026-07-20
Price Target
$83
JPMorgan
$87
2026-07-20
JPMorgan
2026-07-20
Price Target
$87
Morgan Stanley
$78
2026-04-24
Morgan Stanley
2026-04-24
Price Target
$78
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

SS&C Releases 2026 PE Dealmaking Report

SS&C Releases Survey Findings on AI Implementation

SS&C Technologies to Announce Q3 2026 Financial Results

Principal Real Estate Income Fund Declares Monthly Distributions

SS&C Unveils Next-Gen AI Solutions at Annual Conference
SS&C Technologies Holdings, Inc. is a provider of services and software for the financial services and healthcare industries. Its portfolio of products and software-enabled services allows our financial services clients to automate and integrate front-office functions such as trading and modeling, middle-office functions such as portfolio management and reporting, and back-office functions such as accounting, performance measurement, reconciliation, reporting, processing and clearing, and compliance and tax reporting. The Company provides its solutions within the institutional asset and wealth management, alternative investment management, brokerage, retirement, financial advisory and financial institutions vertical markets. It provides solutions to the healthcare industry, including pharmacy, healthcare administration and health outcomes optimization solutions. Its healthcare solutions include claims adjudication, benefit management, care management and business intelligence services. It operates in the Technology sector (SERVICES-PREPACKAGED SOFTWARE industry).
SS&C Technologies is a good buy right now due to its strong fundamentals and positive market sentiment. The current price is $84.07, with a forward P/E ratio of 10.62, suggesting it is undervalued compared to its growth potential. Additionally, the RSI of 84.34 indicates strong momentum, although it is approaching overbought territory. The main risk is the recent YTD change of -1.96%, which reflects broader market pressures, but the company’s solid earnings growth and optimistic forecasts provide a strong counterbalance.
12 analysts cover SSNC: 11 rate it Buy, 1 Hold and 0 Sell. The average price target is 103.29.
No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.